SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Maher H.) "

Sökning: WFRF:(Maher H.)

  • Resultat 21-30 av 72
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  •  
22.
  •  
23.
  •  
24.
  •  
25.
  •  
26.
  • Durno, C., et al. (författare)
  • Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance
  • 2021
  • Ingår i: Journal of Clinical Oncology. - : American Society of Clinical Oncology (ASCO). - 0732-183X .- 1527-7755. ; 39:25
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE Constitutional mismatch repair deficiency syndrome (CMMRD) is a lethal cancer predisposition syndrome characterized by early-onset synchronous and metachronous multiorgan tumors. We designed a surveillance protocol for early tumor detection in these individuals. PATIENTS AND METHODS Data were collected from patients with confirmed CMMRD who were registered in the International Replication Repair Deficiency Consortium. Tumor spectrum, efficacy of the surveillance protocol, and malignant transformation of low-grade lesions were examined for the entire cohort. Survival outcomes were analyzed for patients followed prospectively from the time of surveillance implementation. RESULTS A total of 193 malignant tumors in 110 patients were identified. Median age of first cancer diagnosis was 9.2 years (range: 1.7-39.5 years). For patients undergoing surveillance, all GI and other solid tumors, and 75% of brain cancers were detected asymptomatically. By contrast, only 16% of hematologic malignancies were detected asymptomatically (P < .001). Eighty-nine patients were followed prospectively and used for survival analysis. Five-year overall survival (OS) was 90% (95% CI, 78.6 to 100) and 50% (95% CI, 39.2 to 63.7) when cancer was detected asymptomatically and symptomatically, respectively (P = .001). Patient outcome measured by adherence to the surveillance protocol revealed 4-year OS of 79% (95% CI, 54.8 to 90.9) for patients undergoing full surveillance, 55% (95% CI, 28.5 to 74.5) for partial surveillance, and 15% (95% CI, 5.2 to 28.8) for those not under surveillance (P < .0001). Of the 64 low-grade tumors detected, the cumulative likelihood of transformation from low-to high-grade was 81% for GI cancers within 8 years and 100% for gliomas in 6 years. CONCLUSION Surveillance and early cancer detection are associated with improved OS for individuals with CMMRD.
  •  
27.
  •  
28.
  • Astuti, D, et al. (författare)
  • Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma.
  • 2004
  • Ingår i: British journal of cancer. - : Springer Science and Business Media LLC. - 0007-0920 .- 1532-1827. ; 91:10, s. 1835-41
  • Tidskriftsartikel (refereegranskat)abstract
    • Germline mutations in the succinate dehydrogenase (SDH) (mitochondrial respiratory chain complex II) subunit B gene, SDHB, cause susceptibility to head and neck paraganglioma and phaeochromocytoma. Previously, we did not identify somatic SDHB mutations in sporadic phaeochromocytoma, but SDHB maps to 1p36, a region of frequent loss of heterozygosity (LOH) in neuroblastoma as well. Hence, to evaluate SDHB as a candidate neuroblastoma tumour suppressor gene (TSG) we performed mutation analysis in 46 primary neuroblastomas by direct sequencing, but did not identify germline or somatic SDHB mutations. As TSGs such as RASSF1A are frequently inactivated by promoter region hypermethylation, we designed a methylation-sensitive PCR-based assay to detect SDHB promoter region methylation. In 21% of primary neuroblastomas and 32% of phaeochromocytomas (32%) methylated (and unmethylated) alleles were detected. Although promoter region methylation was also detected in two neuroblastoma cell lines, this was not associated with silencing of SDHB expression, and treatment with a demethylating agent (5-azacytidine) did not increase SDH activity. These findings suggest that although germline SDHB mutations are an important cause of phaeochromocytoma susceptibility, somatic inactivation of SDHB does not have a major role in sporadic neural crest tumours and SDHB is not the target of 1p36 allele loss in neuroblastoma and phaeochromocytoma.
  •  
29.
  • Henderson, Neil C., et al. (författare)
  • Targeting of alpha(v) integrin identifies a core molecular pathway that regulates fibrosis in several organs
  • 2013
  • Ingår i: Nature Medicine. - : Springer Science and Business Media LLC. - 1078-8956 .- 1546-170X. ; 19:12, s. 1617-1624
  • Tidskriftsartikel (refereegranskat)abstract
    • Myofibroblasts are the major source of extracellular matrix components that accumulate during tissue fibrosis, and hepatic stellate cells (HSCs) are believed to be the major source of myofibroblasts in the liver. To date, robust systems to genetically manipulate these cells have not been developed. We report that Cre under control of the promoter of Pdgfrb (Pdgfrb-Cre) inactivates loxP-flanked genes in mouse HSCs with high efficiency. We used this system to delete the gene encoding alpha(v) integrin subunit because various alpha(v)-containing integrins have been suggested as central mediators of fibrosis in multiple organs. Such depletion protected mice from carbon tetrachloride-induced hepatic fibrosis, whereas global loss of beta(3), beta(5) or beta(6) integrins or conditional loss of beta(8) integrins in HSCs did not. We also found that Pdgfrb-Cre effectively targeted myofibroblasts in multiple organs, and depletion of the alpha(v) integrin subunit using this system was protective in other models of organ fibrosis, including pulmonary and renal fibrosis. Pharmacological blockade of alpha(v)-containing integrins by a small molecule (CWHM 12) attenuated both liver and lung fibrosis, including in a therapeutic manner. These data identify a core pathway that regulates fibrosis and suggest that pharmacological targeting of all alpha(v) integrins may have clinical utility in the treatment of patients with a broad range of fibrotic diseases.
  •  
30.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 72
Typ av publikation
tidskriftsartikel (61)
konferensbidrag (2)
bok (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (61)
övrigt vetenskapligt/konstnärligt (4)
Författare/redaktör
MCDONALD, C (12)
Rujescu, D (11)
Werge, T (11)
Mattheisen, M (11)
Cichon, S (10)
Djurovic, S (9)
visa fler...
Mohan, M. (9)
Ali, S (9)
Craddock, N (9)
Giusti-Rodriguez, P (9)
Pata, F (9)
Khatri, C (9)
Gallo, G (9)
Shu, S (9)
Tabiri, S (9)
Hoffmann, P (9)
Youssef, M (9)
Bhangu, A (9)
Williams, S. (8)
Kim, Y. (8)
Moore, R. (8)
Roy, C. (8)
Agartz, I (8)
Andreassen, OA (8)
Melle, I (8)
Patel, P. (8)
Mallet, J. (8)
Powell, J (8)
Mortensen, PB (8)
Kirov, G (8)
St Clair, D (8)
Cox, D (8)
Emile, S (8)
Agarwal, A (8)
Arnaud, AP (8)
Litvin, A (8)
Soreide, K (8)
Saad, MM (8)
Ahmed, A (8)
Bianco, F (8)
Belli, A (8)
Mochet, S (8)
Sasia, D (8)
Lieske, B (8)
Pellino, G (8)
Smith, C (8)
Gala, T (8)
Patel, K (8)
Hammer, C (8)
Cahn, W (8)
visa färre...
Lärosäte
Karolinska Institutet (39)
Göteborgs universitet (14)
Uppsala universitet (9)
Umeå universitet (7)
Lunds universitet (7)
Högskolan Väst (3)
visa fler...
Chalmers tekniska högskola (3)
Kungliga Tekniska Högskolan (2)
Linköpings universitet (2)
Högskolan i Halmstad (1)
Stockholms universitet (1)
Örebro universitet (1)
RISE (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (72)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (23)
Naturvetenskap (14)
Teknik (4)
Lantbruksvetenskap (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy